Cargando…

Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study

BACKGROUND: The role of biologic therapies in the treatment of rheumatoid arthritis has expanded, but dosing patterns in the first versus subsequent lines of therapy have not been thoroughly explored. METHODS: In order to describe patterns of biologic agent utilization among patients with rheumatoid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ogale, Sarika, Hitraya, Elena, Henk, Henry J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184114/ https://www.ncbi.nlm.nih.gov/pubmed/21929807 http://dx.doi.org/10.1186/1471-2474-12-204

Ejemplares similares

Comparison of Biologic Disease-Modifying Antirheumatic Drug Therapy Persistence Between Biologics Among Rheumatoid Arthritis Patients Switching from Another Biologic
por: Johnston, Stephen S., et al.
Publicado: (2014)

Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis
por: Bergman, Martin J., et al.
Publicado: (2014)

Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic
por: Johnston, Stephen S., et al.
Publicado: (2015)

Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis
por: Jansen, Jeroen P, et al.
Publicado: (2014)

Assessing Methotrexate Adherence in Rheumatoid Arthritis: A Cross-Sectional Survey
por: DiBenedetti, Dana B., et al.
Publicado: (2015)

Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study
por: Gilbert, Thomas D, et al.
Publicado: (2004)

Relationship Between Baseline and Early Changes in C‐Reactive Protein and Interleukin‐6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis
por: Wang, Jianmei, et al.
Publicado: (2016)

Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany
por: Neubauer, Sarah, et al.
Publicado: (2014)

Reanalysis of the Multi‐Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic‐Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et al
por: Curtis, Jeffrey R., et al.
Publicado: (2017)

Damage progression in rheumatoid arthritis: the role of biologic agents
por: Favalli, Ennio Giulio
Publicado: (2012)

Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan
por: Mahlich, Jörg, et al.
Publicado: (2016)

Use of Anti-Tumor Necrosis Factor Therapy: A Retrospective Study of Monotherapy and Adherence to Combination Therapy with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs
por: Engel-Nitz, Nicole M., et al.
Publicado: (2015)

Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan
por: Mori, Shunsuke, et al.
Publicado: (2017)

Retrospective Analysis of the Impact of Adalimumab Initiation on Corticosteroid Utilization and Medical Costs Among Biologic-Naïve Patients with Rheumatoid Arthritis
por: Spivey, Christina A., et al.
Publicado: (2019)

Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study
por: Strand, Vibeke, et al.
Publicado: (2012)

Biologic Agents in Rheumatoid Arthritis: An Update for Managed Care Professionals
por: Agarwal, Sandeep K.
Publicado: (2011)

Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals
por: Kiely, Patrick D. W., et al.
Publicado: (2012)

Polymorphisms Involved in Response to Biological Agents Used in Rheumatoid Arthritis
por: Pallio, Giovanni, et al.
Publicado: (2020)

Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
por: Mishra, Richa, et al.
Publicado: (2009)

Effects of Biologic Agents in Patients with Rheumatoid Arthritis and Amyloidosis Treated with Hemodialysis
por: Kuroda, Takeshi, et al.
Publicado: (2016)

Impact of adherence to biological agents on health care resource utilization for patients over the age of 65 years with rheumatoid arthritis
por: Lathia, Urja, et al.
Publicado: (2017)

Dopaminergic Agents in Rheumatoid Arthritis
por: Capellino, Silvia
Publicado: (2019)

Use of biologic agents and methotrexate improves renal manifestation and outcome in patients with rheumatoid arthritis: a retrospective analysis
por: Sawamura, Masato, et al.
Publicado: (2021)

Renal dysfunction among rheumatoid arthritis patients: A retrospective cohort study
por: Oweis, Ashraf O., et al.
Publicado: (2020)

Research on Liver Damage Caused by the Treatment of Rheumatoid Arthritis with Novel Biological Agents or Targeted Agents
por: Zhao, Xin, et al.
Publicado: (2023)

Is there a relationship between periodontitis and rheumatoid arthritis?
por: Ranade, Sarika Bhalgat, et al.
Publicado: (2012)

ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
por: Wang, Michelle, et al.
Publicado: (2023)

Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study
por: Paalanen, Kirsi, et al.
Publicado: (2020)

Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis
por: Bliddal, Sofie, et al.
Publicado: (2017)

Pattern of risks of rheumatoid arthritis among patients using statins: A cohort study with the clinical practice research datalink
por: de Jong, Hilda J. I., et al.
Publicado: (2018)

Erratum to: Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study
por: Paalanen, Kirsi, et al.
Publicado: (2021)

Utilization Patterns of Disease-Modifying Antirheumatic Drugs in Elderly Rheumatoid Arthritis Patients
por: Jin, Xue-Mei, et al.
Publicado: (2014)

Association Between Medicare's National Coverage Determination and Utilization of Next-Generation Sequencing
por: Sheinson, Daniel M., et al.
Publicado: (2021)

Autoreactivity patterns in rheumatoid arthritis
por: Behrens, S, et al.
Publicado: (2001)

Economic impact of biologic utilization patterns in patients with psoriatic arthritis
por: Schwartzman, Sergio, et al.
Publicado: (2017)

Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
por: Das, Priyam, et al.
Publicado: (2023)

Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians
por: Sullivan, Emma, et al.
Publicado: (2020)

Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients
por: Curtis, Jeffrey R., et al.
Publicado: (2020)

A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers
por: Ng, Bernard, et al.
Publicado: (2013)

Ceria-based nanotheranostic agent for rheumatoid arthritis
por: Kalashnikova, Irina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gifr1k7sb5jfqpnjah5fmegs8h